stockrowHaleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) Operating cash flow
Haleon PLC Sponsored ADR's operating cash flow for fiscal 2025 was $3.5B, up 18.1% from $2.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.8B. Over the past ten years it has ranged from $1.0B (fiscal 2019) to $3.5B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 4 consecutive fiscal years. Haleon PLC Sponsored ADR ranks 2nd of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $3.5B | 18.13% |
| FY2024 | $2.9B | 12.57% |
| FY2023 | $2.6B | 2.37% |
| FY2022 | $2.6B | 39.15% |
| FY2021 | $1.8B | (4.86%) |
| FY2020 | $1.9B | 87.56% |
| FY2019 | $1.0B | — |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $11.6B |
| HLN Haleon PLC Sponsored ADR | $4.8B |
| ZTS Zoetis Inc. compare | $2.8B |
| VTRS Viatris Inc. compare | $2.5B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.8B |
| UTHR United Therapeutics Corporation compare | $1.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.1B |
| ELAN Elanco Animal Health Incorporated compare | $617.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $313.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on HLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement